<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC7473320/results/search/disease/results.xml">
  <result pre="of Record : Review: Review In vivo expressed biologics for" exact="infectious disease" post="prophylaxis: rapid delivery of DNA-based antiviral antibodies Emerging Microbes"/>
  <result pre="KEYWORDS Neutralizing antibodies DNA therapeutics antivirals electroporation gene transfer emerging" exact="infectious disease" post="antibody cocktail fig-count: table-count: equation-count: ref-count: page-count: Introduction Unmet"/>
  <result pre="fig-count: table-count: equation-count: ref-count: page-count: Introduction Unmet needs of emerging" exact="infectious disease" post="outbreaks Fuelled by multiple factors, including the growing urbanization"/>
  <result pre="outbreaks have caused significant damage with wide-reaching ramifications. From the" exact="severe acute respiratory syndrome" post="(SARS) outbreak in 2003, the H1N1 influenza A virus"/>
  <result pre="severe acute respiratory syndrome (SARS) outbreak in 2003, the H1N1" exact="influenza" post="A virus (IAV) pandemic in 2009, the Middle East"/>
  <result pre="recurring Ebola virus outbreaks in 2014–2016, to the expansion of" exact="chikungunya" post="virus and the rapid spreading of Zika virus infections"/>
  <result pre="and private sectors [6]. Because of the existing infrastructure for" exact="influenza" post="vaccine development, vaccines against the 2009 H1N1 pandemic IAV"/>
  <result pre="authorization from the FDA [14]. Antibodies as drugs for fighting" exact="infectious disease" post="Monoclonal antibodies (mAbs) represent a unique class of biologic"/>
  <result pre="diseases. A few, however, have been approved for use in" exact="infectious disease" post="settings, such as palivizumab for respiratory syncytial virus and"/>
  <result pre="mAb Fc domain [20]. This is of particular importance in" exact="infectious disease" post="settings that are susceptible to Fc receptor-mediated antibody dependent"/>
  <result pre="major barrier to the more widespread use of mAbs for" exact="infectious disease" post="[17]. However, the use of mAbs as therapeutics in"/>
  <result pre="not the least of which is the global eradication of" exact="smallpox" post="and massive reductions in the number of other viral"/>
  <result pre="in the number of other viral diseases like polio and" exact="measles" post="through vaccination [28]. Similarly, the development of a vast"/>
  <result pre="inert [31]. And although historically the delivery of mAbs for" exact="infectious disease" post="prevention and therapy has been a much smaller area"/>
  <result pre="first clinical use was in 1995 for the treatment of" exact="cystic fibrosis." post="The first regulatory approval didn’t come until 2012, however,"/>
  <result pre="by Moderna (www.clinicaltrials.gov Identifier: NCT03829384), for an antibody directed against" exact="chikungunya" post="virus. In contrast to the long-lived expression often seen"/>
  <result pre="LNP-mRNA has successfully been used to deliver NAbs against HIV-1," exact="influenza" post="B virus, or rabies virus in mice, resulting in"/>
  <result pre="used to deliver NAbs against HIV-1, influenza B virus, or" exact="rabies" post="virus in mice, resulting in peak titers of ∼10–150 µg/mL"/>
  <result pre="antibodies, either as therapeutic agents or for the prevention of" exact="infectious disease" post="(Table 1) [48,49]. Table 1. DNA/EP-mediated delivery of antiviral"/>
  <result pre="1) [48,49]. Table 1. DNA/EP-mediated delivery of antiviral mAbs for" exact="infectious disease" post="prophylaxis. Virus Antibody Reference Influenza A rHA Yamazaki et"/>
  <result pre="subsequent study revealed the benefit of cardiotrophin-1 delivery for progressive" exact="motor neuron disease" post="[47,57]. It was nearly a decade later, however, before"/>
  <result pre="lethal IAV challenge [58]. In another important model of DNA/EP-mediated" exact="infectious disease" post="prophylaxis, the delivery of an anti-dengue virus NAb bearing"/>
  <result pre="the prevention of infectious diseases, including not only IAV, but" exact="influenza" post="B virus, chikungunya virus, Ebola virus, and Zika virus"/>
  <result pre="infectious diseases, including not only IAV, but influenza B virus," exact="chikungunya" post="virus, Ebola virus, and Zika virus [60–65.] Importantly, the"/>
  <result pre="An important advantage revealed by some of these studies of" exact="infectious disease" post="prophylaxis, but with relevance to other disease indications that"/>
  <result pre="makes this highly attractive strategy of administering NAb cocktails for" exact="infectious disease" post="a much more realistic possibility, particularly when the goal"/>
  <result pre="References References 1SmithKF, GoldbergM, RosenthalS, et al.Global rise in human" exact="infectious disease" post="outbreaks. J Roy Soc Interface. 2014;11:20140950. doi: 10.1098/rsif.2014.095025401184 2FindlaterA,"/>
  <result pre="2002;11:1615–1625. doi: 10.1093/hmg/11.14.161512075006 58YamazakiT, NagashimaM, NinomiyaD, et al.Passive immune-prophylaxis against" exact="influenza" post="virus infection by the expression of neutralizing anti-hemagglutinin monoclonal"/>
  <result pre="al.DMAb inoculation of synthetic cross reactive antibodies protects against lethal" exact="influenza" post="A and B infections. npj Vaccines. 2017;2:18. doi: 10.1038/s41541-017-0020-x29263874"/>
  <result pre="immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against" exact="chikungunya" post="virus. J Infect Dis. 2016;214:369–378. doi: 10.1093/infdis/jiw11127001960 62AndrewsCD, LuoY,"/>
  <result pre="monoclonal antibodies by gene transfer via electroporation protects against lethal" exact="influenza" post="and Ebola infections. Mol Ther Methods Clin Dev. 2017;7:74–82."/>
  <result pre="et al.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19," exact="acute respiratory distress syndrome," post="and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331."/>
 </snippets>
</snippetsTree>
